NeuroSearch to present at the 2008 UBS Global Life Science Conference in New York

Investor News



NeuroSearch to present at the 2008 UBS Global Life Science Conference in 
New York

NeuroSearch will make a presentation at the 2008 UBS Global Life Science
Conference to be held 22 - 25 September in New York. 

NeuroSearch's presentation is scheduled for:
Wednesday, 24 September at 1:30 p.m. local time 
and will be held by CEO Flemming Pedersen.

The presentation will be webcasted and the link to access the audio webcast
will be available at www.neurosearch.com together with the powerpoint
presentation just before the presentation will be held at the conference. The
audio webcast will be available until 25 October 2008. 



Contact person: 
Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications,
telephone: +45 4460 8212 or +45 4017 5103 





NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the
OMX Nordic Exchange Copenhagen A/S. The company's core business covers the
development of novel drugs, based on a broad and well-established drug
discovery platform focusing on ion channels and CNS disorders. A substantial
share of its activities is partner financed through a broad alliance with
GlaxoSmithKline (GSK) and collaborations with, among others, Abbott and
Astellas. NeuroSearch's drug pipeline comprises 14 clinical (Phase I-III)
development programmes: ACR16 for Huntington's disease (Phase III), tesofensine
for obesity and in Type 2 diabetes (Phase III in preparation), NS2359 for
depression (Phase II) and ADHD (Phase II) in partnership with GSK, ABT-894 for
ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 for
schizophrenia (Phase I) in partnership with Astellas, ACR325 for Parkinson's
disease (Phase II in preparation) and bipolar disorder (Phase II in
preparation), ABT-107 and ABT-560 for the treatment of various CNS disorders -
both (Phase I) in collaboration with Abbott, NSD-644 for pain (Phase I) in
partnership with GSK, ACR343 for Parkinson's disease (Phase I) and NSD-788 for
anxiety/depression (Phase I). In addition, NeuroSearch has a broad portfolio of
preclinical drug candidates and holds equity interests in several biotech
companies.